These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 32931028

  • 1. Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis.
    Isidro RA, Ruan AB, Gannarapu S, Raj D, Rahma O, Grover S, Srivastava A.
    Histopathology; 2021 Mar; 78(4):532-541. PubMed ID: 32931028
    [Abstract] [Full Text] [Related]

  • 2. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
    Wong JSL, Kwok GGW, Tang V, Li BCW, Leung R, Chiu J, Ma KW, She WH, Tsang J, Lo CM, Cheung TT, Yau T.
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
    [Abstract] [Full Text] [Related]

  • 3. Immune checkpoint inhibitor-induced diarrhea: Clinicopathological study of 11 patients.
    Yanai S, Nakamura S, Kawasaki K, Toya Y, Akasaka R, Oizumi T, Ishida K, Sugai T, Matsumoto T.
    Dig Endosc; 2020 May; 32(4):616-620. PubMed ID: 31595568
    [Abstract] [Full Text] [Related]

  • 4. Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.
    Chanson N, Ramos-Casals M, Pundole X, Suijkerbuijk K, José de Barros E Silva M, Lidar M, Benesova K, Leipe J, Acar-Denizli N, Pradère P, Michot JM, Voisin AL, Suárez-Almazor ME, Radstake TRD, Fernandes Moça Trevisani V, Schulze-Koops H, Melin A, Robert C, Mariette X, Baughman RP, Lambotte O, ICIR, Coordination, Co-Convenors, Steering Committee, Research Fellows, Data Scientist.
    Eur J Cancer; 2021 Nov; 158():208-216. PubMed ID: 34452793
    [Abstract] [Full Text] [Related]

  • 5. Central nervous system complications associated with immune checkpoint inhibitors.
    Vogrig A, Muñiz-Castrillo S, Joubert B, Picard G, Rogemond V, Marchal C, Chiappa AM, Chanson E, Skowron F, Leblanc A, Ducray F, Honnorat J.
    J Neurol Neurosurg Psychiatry; 2020 Jul; 91(7):772-778. PubMed ID: 32312871
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Immune checkpoint inhibitor induced colitis: A nationwide population-based study.
    Farha N, Alkhayyat M, Lindsey A, Mansoor E, Saleh MA.
    Clin Res Hepatol Gastroenterol; 2022 Jan; 46(1):101778. PubMed ID: 34332139
    [Abstract] [Full Text] [Related]

  • 8. Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors.
    Rahma OE, Reuss JE, Giobbie-Hurder A, Shoja E Razavi G, Abu-Shawer O, Mehra P, Gupta S, Simon R, Khleif SN.
    Clin Cancer Res; 2021 Jan 15; 27(2):485-491. PubMed ID: 33082209
    [Abstract] [Full Text] [Related]

  • 9. Morphological spectrum of immune check-point inhibitor therapy-associated gastritis.
    Johncilla M, Grover S, Zhang X, Jain D, Srivastava A.
    Histopathology; 2020 Mar 15; 76(4):531-539. PubMed ID: 31692018
    [Abstract] [Full Text] [Related]

  • 10. Recognizing encephalopathy in immune checkpoint inhibitor therapy: A single-center experience.
    Wei D, Zhou DJ, Datta P, Taraschenko O.
    Cancer Med; 2021 May 15; 10(9):2978-2986. PubMed ID: 33660430
    [Abstract] [Full Text] [Related]

  • 11. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
    Sun MM, Kelly SP, Mylavarapu Bs AL, Holland GN, Coleman AL, Yu F, Hsu Ms S, Lum F, Gordon LK.
    Ophthalmology; 2021 Jun 15; 128(6):910-919. PubMed ID: 33166553
    [Abstract] [Full Text] [Related]

  • 12. From ICI to ICU: Ipilimumab and Nivolumab-Induced Immune Checkpoint Inhibitor Colitis.
    Zhou W, Frye J, Soroudi C, Triadafilopoulos G, Berry R.
    Dig Dis Sci; 2022 Mar 15; 67(3):800-803. PubMed ID: 34159488
    [No Abstract] [Full Text] [Related]

  • 13. Quality of life under treatment with the immune checkpoint inhibitors ipilimumab and nivolumab in melanoma patients. Real-world data from a prospective observational study at the Skin Cancer Center Kiel.
    Grote C, Bohne AS, Blome C, Kähler KC.
    J Cancer Res Clin Oncol; 2024 Oct 10; 150(10):454. PubMed ID: 39387946
    [Abstract] [Full Text] [Related]

  • 14. Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review.
    Dupré A, Michot JM, Schoeffler A, Frumholtz L, Baroudjian B, Delyon J, Lebbe C, Lambotte O.
    Br J Haematol; 2020 Jun 10; 189(5):985-992. PubMed ID: 32243578
    [No Abstract] [Full Text] [Related]

  • 15. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
    Sussman TA, Li H, Hobbs B, Funchain P, McCrae KR, Khorana AA.
    J Immunother Cancer; 2021 Jan 10; 9(1):. PubMed ID: 33436486
    [Abstract] [Full Text] [Related]

  • 16. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.
    Iyer PC, Cabanillas ME, Waguespack SG, Hu MI, Thosani S, Lavis VR, Busaidy NL, Subudhi SK, Diab A, Dadu R.
    Thyroid; 2018 Oct 10; 28(10):1243-1251. PubMed ID: 30132401
    [Abstract] [Full Text] [Related]

  • 17. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
    Pires da Silva I, Ahmed T, Reijers ILM, Weppler AM, Betof Warner A, Patrinely JR, Serra-Bellver P, Allayous C, Mangana J, Nguyen K, Zimmer L, Trojaniello C, Stout D, Lyle M, Klein O, Gerard CL, Michielin O, Haydon A, Ascierto PA, Carlino MS, Lebbe C, Lorigan P, Johnson DB, Sandhu S, Lo SN, Blank CU, Menzies AM, Long GV.
    Lancet Oncol; 2021 Jun 10; 22(6):836-847. PubMed ID: 33989557
    [Abstract] [Full Text] [Related]

  • 18. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
    Hultin S, Nahar K, Menzies AM, Long GV, Fernando SL, Atkinson V, Cebon J, Wong MG.
    BMC Nephrol; 2020 Sep 07; 21(1):391. PubMed ID: 32894101
    [Abstract] [Full Text] [Related]

  • 19. Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
    Kitagataya T, Suda G, Nagashima K, Katsurada T, Yamamoto K, Kimura M, Maehara O, Yamada R, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Komatsu Y, Hata H, Takeuchi S, Abe T, Sakakibara-Konishi J, Teshima T, Homma A, Sakamoto N.
    J Gastroenterol Hepatol; 2020 Oct 07; 35(10):1782-1788. PubMed ID: 32187734
    [Abstract] [Full Text] [Related]

  • 20. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.
    Ali AK, Watson DE.
    Pharmacotherapy; 2017 Nov 07; 37(11):1383-1390. PubMed ID: 28950039
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.